Teichmann Pedro do Valle, Moschetta Marina Oliboni, Franco Rodrigo Fontanive, Vicari Alessandra Rosa, Nunes Gérson Luiz da Silva, Lazzaretti Maria Angela Kalil Nader, Gomes Miriam Gressler, Dorigoni Silvia Maria, Dall'Agnol Paulo Roberto, Klafke Adriana, Thomé Fernando Saldanha, Spuldaro Fabio, Agra Homero, Almeida Rafael de, Lara Darlan Martins, Bauer Andrea Carla, Karhol Cristina, Manfro Roberto Ceratti
Hospital de Clínicas de Porto Alegre, Divisão de Nefrologia, Porto Alegre, RS, Brazil.
Hospital de Clínicas de Porto Alegre, Divisão de Transplante, Porto Alegre, RS, Brazil.
J Bras Nefrol. 2023 Apr-Jun;45(2):210-217. doi: 10.1590/2175-8239-JBN-2022-0034en.
Patients on renal replacement therapy (RRT) and kidney transplant recipients (KTR) present multiple factors that may increase the risk of death from coronavirus disease 2019 (COVID-19). This study aimed to evaluate the incidence and impact of COVID-19 in RRT patients and KTRs.
Between March 2020 and February 2021, we monitored the RRT population of thirteen dialysis facilities that refer patients for transplantation to our center, a tertiary hospital in Southern Brazil. In the same period, we also monitor COVID-19 incidence and mortality in our KTR population. Demographical, clinical, and COVID-19-related information were analyzed.
We evaluated 1545 patients in the dialysis centers, of which 267 (17.4%) were infected by COVID-19 and 53 (19.9%) died. Among 275 patients on the kidney transplant waiting list, 63 patients (22.9%) were infected and seven (11.1%) died. COVID-19 was the leading cause of death (29.2%) among patients on the waiting list. Within the population of 1360 KTR, 134 (9.85%) were diagnosed with COVID-19 and 20 (14.9%) died. The number of kidney transplants decreased by 56.7% compared with the same period in the previous twelve months.
In the study period, patients on RRT and KTRs presented a high incidence of COVID-19 and high COVID-19-related lethality. The impact on the patients on the transplant waiting list was less pronounced. The lethality rate observed in both cohorts seems to be related to age, comorbidities, and disease severity.
接受肾脏替代治疗(RRT)的患者和肾移植受者(KTR)存在多种因素,可能增加感染2019冠状病毒病(COVID-19)死亡的风险。本研究旨在评估COVID-19在RRT患者和KTR中的发病率及影响。
2020年3月至2021年2月期间,我们监测了13个透析机构的RRT人群,这些机构会将患者转介至我们位于巴西南部的一家三级医院进行移植。同期,我们还监测了我们KTR人群中的COVID-19发病率和死亡率。对人口统计学、临床及与COVID-19相关的信息进行了分析。
我们评估了透析中心的1545例患者,其中267例(17.4%)感染了COVID-19,53例(19.9%)死亡。在275例肾移植等待名单上的患者中,63例(22.9%)感染,7例(11.1%)死亡。COVID-19是等待名单上患者的主要死亡原因(29.2%)。在1360例KTR人群中,134例(9.85%)被诊断为COVID-19,20例(14.9%)死亡。与前十二个月同期相比,肾移植数量减少了56.7%。
在研究期间,RRT患者和KTR中COVID-19发病率高,且与COVID-19相关的致死率高。对移植等待名单上患者的影响不太明显。两个队列中观察到的致死率似乎与年龄、合并症和疾病严重程度有关。